Table 3.
Assessments of the influence of different groups on the price of a new drug (italic emphasis indicates correct responses, as determined by content experts)
| Most influential N (%) | Somewhat influential N (%) | Not influential N (%) | Don’t know N (%) | |
|---|---|---|---|---|
| Drug companies | 226 (94.17) | 5 (2.08) | 0 | 9 (3.75) |
| Insurance companies | 205 (85.42) | 20 (8.33) | 5 (2.08) | 10 (4.17) |
| Pharmacy benefit managers | 85 (35.42) | 87 (36.25) | 29 (12.08) | 39 (16.25) |
| Medicare/Medicaid | 111 (46.25) | 86 (35.83) | 22 (9.17) | 21 (8.75) |
| Pharmacies | 69 (28.75) | 100 (41.67) | 50 (20.83) | 21 (8.75) |
| Congress | 62 (25.83) | 116 (48.33) | 38 (15.83) | 24 (10.00) |
| Wholesalers | 60 (25.00) | 116 (48.33) | 24 (10.00) | 40 (16.67) |
| Hospitals/clinics | 44 (18.33) | 108 (45.00) | 68 (28.33) | 20 (8.33) |
| Patient advocacy groups | 6 (2.50) | 99 (41.25) | 104 (43.33) | 31 (12.92) |
| International pricing committees | 56 (23.33) | 112 (46.67) | 36 (15.00) | 36 (15.00) |
| Food and Drug Administration | 50 (20.83) | 85 (35.42) | 81 (33.75) | 24 (10.00) |
| National Institutes of Health | 13 (5.42) | 84 (35.00) | 112 (46.67) | 31 (12.92) |
| Professional medical societies | 10 (4.17) | 108 (45.00) | 91 (37.92) | 31 (12.92) |
| Private practices | 6 (2.50) | 72 (30.00) | 133 (55.42) | 29 (12.08) |